Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy
- PMID: 40096545
- DOI: 10.1093/cid/ciaf120
Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy
Abstract
Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with HIV (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH with adherence difficulties remained on therapy and virally suppressed 48-weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.
Keywords: Long-acting injectables; adherence challenges; cabotegravir-rilpivirine; people living with HIV; viremia.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Grants and funding
LinkOut - more resources
Full Text Sources